CytoMed Therapeutics (GDTC) Shares Outstanding (2021 - 2025)

CytoMed Therapeutics has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $11.8 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 2.5% year-over-year to $11.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.8 million (up 2.5% YoY) and the FY2025 annual result came in at $11.8 million, up 2.5% from the prior year.
• Shares Outstanding (Entity) improved to $11.8 million in Q4 2025 per GDTC's latest filing, from $11.5 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $11.8 million in Q4 2025 and troughed at $7.5 million in Q4 2021.
• A 5-year average of $10.1 million and a median of $11.5 million in 2023 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) jumped 45.8% in 2023, then changed 0.0% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $7.5 million in 2021, then climbed by 5.82% to $7.9 million in 2022, then surged by 45.8% to $11.5 million in 2023, then changed by 0.0% to $11.5 million in 2024, then climbed by 2.5% to $11.8 million in 2025.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $11.8 million, $11.5 million, and $11.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.